Title | Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. |
Publication Type | Journal Article |
Year of Publication | 2010 |
Authors | Petersen, RC, Aisen, PS, Beckett, LA, Donohue, MC, Gamst, AC, Harvey, DJ, Jack, CR, Jagust, WJ, Shaw, LM, Toga, AW, Trojanowski, JQ, Weiner, MW |
Journal | Neurology |
Volume | 74 |
Issue | 3 |
Pagination | 201-9 |
Date Published | 2010 Jan 19 |
ISSN | 1526-632X |
Keywords | Aged, Aged, 80 and over, Alzheimer Disease, Biomarkers, Cross-Sectional Studies, Diagnostic Imaging, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged |
Abstract | BACKGROUND: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally. OBJECTIVE: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures. METHODS: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials. RESULTS: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Abeta-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures. CONCLUSION: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months. |
DOI | 10.1212/WNL.0b013e3181cb3e25 |
Alternate Journal | Neurology |
PubMed ID | 20042704 |
PubMed Central ID | PMC2809036 |
Grant List | 1 R01 DA017830 / DA / NIDA NIH HHS / United States 1 R01 EB 006266-01 / EB / NIBIB NIH HHS / United States 1 R01 NS049194 / NS / NINDS NIH HHS / United States 1 R01 NS050792 / NS / NINDS NIH HHS / United States 1 U01 AG 024904-05 / AG / NIA NIH HHS / United States 1 U01 AG024904 / AG / NIA NIH HHS / United States 1 U01 AG24904 / AG / NIA NIH HHS / United States 1 U54 EB05149 / EB / NIBIB NIH HHS / United States 1KL2RR024144-01 / RR / NCRR NIH HHS / United States 1P01 AG-19724-07 / AG / NIA NIH HHS / United States 1R01 HD053893-01 / HD / NICHD NIH HHS / United States 1R01MH072641-01A1 / MH / NIMH NIH HHS / United States 1RC2AG036535-01 / AG / NIA NIH HHS / United States 1U01AG24904 / AG / NIA NIH HHS / United States 2 P30 CA93373 / CA / NCI NIH HHS / United States 2 P30AG10129 / AG / NIA NIH HHS / United States 2 P50 AG016570 / AG / NIA NIH HHS / United States 2 R01LM005639 / LM / NLM NIH HHS / United States 2P30AG10129 / AG / NIA NIH HHS / United States 2P50AG005133 / AG / NIA NIH HHS / United States 5 P41 RR013642 / RR / NCRR NIH HHS / United States 5 R01 MH071940 / MH / NIMH NIH HHS / United States 5 U24 RR021760 / RR / NCRR NIH HHS / United States 5 U54 RR021813 / RR / NCRR NIH HHS / United States 5R01EB002138-07 / EB / NIBIB NIH HHS / United States 9 P01 EB 001955-11 / EB / NIBIB NIH HHS / United States AG 024904 / AG / NIA NIH HHS / United States AG010483 / AG / NIA NIH HHS / United States AG024904 / AG / NIA NIH HHS / United States AG027859 / AG / NIA NIH HHS / United States AG027984 / AG / NIA NIH HHS / United States AG031224 / AG / NIA NIH HHS / United States AG11378 / AG / NIA NIH HHS / United States CA104573 / CA / NCI NIH HHS / United States DK075128 / DK / NIDDK NIH HHS / United States HL095089 / HL / NHLBI NIH HHS / United States MH062512 / MH / NIMH NIH HHS / United States MH069433 / MH / NIMH NIH HHS / United States MH079752 / MH / NIMH NIH HHS / United States MH083506 / MH / NIMH NIH HHS / United States MH083552 / MH / NIMH NIH HHS / United States MH22005 / MH / NIMH NIH HHS / United States P01 AG 09215-20 / AG / NIA NIH HHS / United States P01 AG 17586-10 / AG / NIA NIH HHS / United States P01AG012435 / AG / NIA NIH HHS / United States P01AG19724 / AG / NIA NIH HHS / United States P30 AG 10124-18 / AG / NIA NIH HHS / United States P30 AG010129 / AG / NIA NIH HHS / United States P30 AG010129-20 / AG / NIA NIH HHS / United States P30AG036468 / AG / NIA NIH HHS / United States P41 RR023953 / RR / NCRR NIH HHS / United States P50 AG16574 / AG / NIA NIH HHS / United States P50 NS053488-02 / NS / NINDS NIH HHS / United States P50-AG16574 / AG / NIA NIH HHS / United States P50AG23501 / AG / NIA NIH HHS / United States R01 AG10897 / AG / NIA NIH HHS / United States R01 AG11378 / AG / NIA NIH HHS / United States R01 HD050735-01 / HD / NICHD NIH HHS / United States R01 MH069259 / MH / NIMH NIH HHS / United States R01 NS031966 / NS / NINDS NIH HHS / United States R01-AG030048 / AG / NIA NIH HHS / United States R01-AG16381 / AG / NIA NIH HHS / United States R01AG029672 / AG / NIA NIH HHS / United States R01AG031252 / AG / NIA NIH HHS / United States R24 RR021382 / RR / NCRR NIH HHS / United States R24 RR021992 / RR / NCRR NIH HHS / United States RC1AG035427 / AG / NIA NIH HHS / United States RC2NS069368 / NS / NINDS NIH HHS / United States RL1NS062412 / NS / NINDS NIH HHS / United States U01 AG 024904 / AG / NIA NIH HHS / United States U01 AG024904 / AG / NIA NIH HHS / United States U01 AG06786 / AG / NIA NIH HHS / United States U01-AG024904 / AG / NIA NIH HHS / United States U01-AG10483 / AG / NIA NIH HHS / United States U01AG024904 / AG / NIA NIH HHS / United States UO1 AG029213-01 / AG / NIA NIH HHS / United States |
- Comment
|